Evidence map›Paper›PMID 31828431›Full record

ReviewVirchows Archiv : an international journal of pathology2020

What's new in fibroblastic tumors?

Susan M Armstrong, Elizabeth G Demicco

Abstract readReview
PubMed Publisher
In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. The Recent Advances in Molecular Diagnosis of Soft Tissue Tumors.International journal of molecular sciences · 2023
    Review
  2. Overlapping morphological, immunohistochemical and genetic features of superficial CD34-positive fibroblastic tumor and PRDM10-rearranged soft tissue tumor.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Article
  3. Article
  4. Frontiers in oncology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Susan M ArmstrongDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Elizabeth G DemiccoDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. Elizabeth.Demicco@SinaiHealthSystem.ca.ORCID https://orcid.org/0000-0003-4144-8824

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the last 10 years, a number of advances have been made in our understanding of fibroblastic and myofibroblastic tumors. The rapidly evolving field of molecular diagnostics has resulted in the recognition of new entities and better understanding of tumor pathogenesis, while careful clinicopathologic correlative analyses have led to improvements in modeling tumor behavior. This review will discuss new and emerging entities in fibroblastic neoplasia and provide updates on the pathogenesis, diagnosis, and prognostication of these diverse and challenging tumors.

Indexed as

Antigens, CD34FibroblastsGene RearrangementHumansNeoplasms, Fibrous TissuePrognosisRNA-Binding Protein EWSSarcomaSmad3 ProteinSoft Tissue NeoplasmsAntigens, CD34EWSR1 protein, humanRNA-Binding Protein EWSSmad3 ProteinSMAD3 protein, humanFibroblastic tumorsMolecular diagnosticsMyofibroblastic tumorsPrognosis

Identifiers

PMID31828431

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.